| Sažetak | Cilj istraživanja: Svrha ovog istraživanja bila je usporediti serumske koncentracije adropina i biokemijskih parametara u bolesnika s Crohnovom bolesti i kontrolnih ispitanika.
Materijali i metode: Ovo presječno kliničko istraživanje provedeno je u Kliničkom bolničkom centru Split i Medicinskom fakultetu u Splitu tijekom razdoblja od 1. prosinca 2017. do 1. lipnja 2018. godine, a obuhvatilo je ukupno 30 odraslih bolesnika s Crohnovom bolesti i 30 kontrolnih ispitanika, usklađenih prema dobi i spolu. Svim ispitanicima uzeti su detaljni anamnestički podatci te izvršen fizikalni pregled i mjerenja antropometrijskih obilježja. Serum je dobiven centrifugom iz uzoraka venske krvi ispitanika te su iz njega određene koncentracije adropina i drugih biokemijskih parametara. Serumske koncentracije adropina određene su koristeći dvostruki enzim-imunoadsorpcijski test (ELISA) humanog adropina (Phoenix Pharmaceuticals, Burlingame, CA, SAD), prema uputama proizvođača.
Rezultati: Pronađeno je da su serumske koncentracije adropina statistički značajno niže u bolesnika s Crohnovom bolesti u odnosu na kontrolnu skupinu (2,66±0,53 vs. 3,22±0,61 ng/mL; P=0,002), ali nije pronađena statistički značajna razlika kod usporedbe bolesnika s aktivnom i bolesnika s inaktivnom Crohnovom bolesti (2,66±0,31 vs. 2,67±0,72 ng/mL; P=0,969). Također, nisu pronađene statistički značajne razlike u promatranim biokemijskim parametrima između bolesnika s Crohnovom bolesti i kontrolne skupine, osim u vrijednostima CRP-a koji je bio značajno viši u bolesnika s Crohnovom bolesti (18,86±38,19 vs. 1,39±1,36 mg/L; P=0,017). Nadalje, pronađena je statistički značajna pozitivna korelacija serumske koncentracije adropina s koncentracijom HDL-a (r=0,311; P=0,038) i LDL-a (r=0,322; P=0,031) te negativna korelacija s koncentracijom CRP-a (r=-0,303; P=0,041).
Zaključci: Naše istraživanje pokazalo je da su serumske koncentracije adropina značajno niže u bolesnika s Crohnovom bolesti u usporedbi s kontrolnom skupinom, što upućuje da adropin sudjeluje u složenoj patofiziologiji Crohnove bolesti. |
| Sažetak (engleski) | Aim of the study: The purpose of this study was to compare serum concentrations of adropin and biochemical parameters in patients with Crohn's disease and control subjects.
Materials and Methods: This cross-sectional clinical study was conducted at the University Hospital of Split and University of Split School of Medicine during the period from 1st of December 2017 to 1st of June 2018, and included a total of 30 adult patients with Crohn's disease and 30 control subjects, matched with age and sex. All subjects underwent detailed anamnestic data, physical examination and measurement of anthropometric characteristics. The serum was obtained by centrifugation from the sample of venous blood of the subjects and from it concentrations of adropin and other biochemical parameters were determined. Serum concentrations of adropin were determined using a double enzyme-immunoadsorbent assay (ELISA) of human adropin (Phoenix Pharmaceuticals, Burlingame, CA, USA), according to the manufacturer's instructions.
Results: Serum concentrations of adropin were statistically significantly lower in patients with Crohn's disease compared to the control group (2.66 ± 0.53 vs. 3.22 ± 0.61 ng / mL; P = 0.002) but a statistically significant difference wasn't found in the comparison of patients with active and patients with inactive Crohn's disease (2.66 ± 0.31 vs. 2.67 ± 0.72 ng / mL; P = 0.969). Also, no statistically significant difference was observed in the biochemical parameters between patients with Crohn's disease and control group, except in CRP values which were significantly higher in patients with Crohn's disease (18.86 ± 38.19 versus 1.39 ± 1.36 mg / L; P = 0.017). Furthermore, a statistically significant positive correlation was found between serum concentrations of adropin with HDL (r = 0.311; P = 0.038) and LDL concentrations (r = 0.322; P = 0.031), and a negative correlation with CRP concentration (r = 0.303; P = 0.041).
Conclusion: Our study showed that serum concentrations of adropin were significantly lower in patients with Crohn's disease compared to the control group, indicating that adropin may be involved in the complicated pathophysiology of Crohn's disease. |
